Non-Invasive Prenatal Testing Market Size, Share & Trends Analysis Report, By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Pregnancy Risk (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests), By Technology, By Product, By Application, By End-User, By Region, Forecasts, 2024-2031
Segmentation of Non-Invasive Prenatal Testing Market
Non-Invasive Prenatal Testing Market- By Gestation Period
- 0-12 Weeks
- 13-24 Weeks
- 25-36 Weeks
Non-Invasive Prenatal Testing Market- By Pregnancy Risk
- High & Average Risk
- Low Risk
Non-Invasive Prenatal Testing Market- By Method
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
Non-Invasive Prenatal Testing Market- By Technology
- NGS
- Array Technology
- PCR
- Others
Non-Invasive Prenatal Testing Market- By Product
- Consumables & Reagents
- Instruments
Non-Invasive Prenatal Testing Market- By Application
- Trisomy
- Microdeletion Syndrome
- Other Applications
Non-Invasive Prenatal Testing Market- By End-use
- Hospitals & Clinics
- Diagnostic Laboratories
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-Invasive Prenatal Testing Market Snapshot
Chapter 4. Global Non-Invasive Prenatal Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Gestation Period Estimates & Trend Analysis
5.1. by Gestation Period & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Gestation Period:
5.2.1. 0-12 Weeks
5.2.2. 13-24 Weeks
5.2.3. 25-36 Weeks
Chapter 6. Market Segmentation 2: by Pregnancy Risk Estimates & Trend Analysis
6.1. by Pregnancy Risk & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Pregnancy Risk:
6.2.1. High & Average Risk
6.2.2. Low Risk
Chapter 7. Market Segmentation 3: by Method Estimates & Trend Analysis
7.1. by Method & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Method:
7.2.1. Ultrasound Detection
7.2.2. Biochemical Screening Tests
7.2.3. Cell-Free DNA in Maternal Plasma Tests
Chapter 8. Market Segmentation 4: by Technology Estimates & Trend Analysis
8.1. by Technology & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
8.2.1. NGS
8.2.2. Array Technology
8.2.3. PCR
8.2.4. Others
Chapter 9. Market Segmentation 5: by Product Estimates & Trend Analysis
9.1. by Product & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
9.2.1. Consumables & Reagents
9.2.2. Instruments
Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis
10.1. by Application & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
10.2.1. Trisomy
10.2.2. Microdeletion Syndrome
10.2.3. Other Applications
Chapter 11. Market Segmentation 7: by End-Use Estimates & Trend Analysis
11.1. by End-Use & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Use:
11.2.1. Hospitals & Clinics
11.2.2. Diagnostic Laboratories
Chapter 12. Non-Invasive Prenatal Testing Market Segmentation 3: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.1.2. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.1.3. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.1.4. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.1.5. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.1.6. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.1.7. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.1.8. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.2. Europe
12.2.1. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.2.2. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.2.3. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.2.4. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.2.5. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.2.6. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.2.7. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.2.8. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.3. Asia Pacific
12.3.1. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.3.2. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.3.3. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.3.4. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.3.5. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.3.6. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.3.7. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.3.8. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.4. Latin America
12.4.1. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.4.2. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.4.3. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.4.4. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.4.5. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.4.6. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.4.7. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.4.8. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.5. Middle East & Africa
12.5.1. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.5.2. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.5.3. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.5.4. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.5.5. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.5.6. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.5.7. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.5.8. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Genesis Genetics (CooperSurgical, Inc.)
13.2.2. Natera, Inc.
13.2.3. Eurofins LifeCodexx GmbH
13.2.4. Illumina, Inc. (Verinata Health, Inc.)
13.2.5. Centogene N.V.
13.2.6. MedGenome Labs Ltd.
13.2.7. Myriad Women’s Health, Inc. (Counsyl, Inc.)
13.2.8. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
13.2.9. Qiagen
13.2.10. Laboratory Corp. of America Holdings
13.2.11. Progenity, Inc.
13.2.12. Quest Diagnostics, Inc.
13.2.13. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031.
The Non-Invasive Prenatal Testing Market is expected to grow at a 13.02 % CAGR during the forecast period for 2024-2031.
Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Lab